Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot EEG crossover study of CT1812 in mild to moderate Alzheimer's disease
NL-OMON54794Phase 2Active, not recruiting
- Sponsor
- Julius Clinical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zervimesine in Alzheimer's disease (AD) (2 arms), sponsored by Julius Clinical. Primary endpoints: Adverse events, Physical examinations and 12 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON54794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54794.